Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.8700 (-5.65%) ($12.6600 - $13.7400) on Wed. Apr. 17, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.24% (three month average) | RSI | 46 | Latest Price | $12.8700(-5.65%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.9% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.6% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(61%) XBI(57%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.62% in a week (0% probabilities). VXX(-14%) TLT(-14%) UUP(-13%) VIXM(-8%) IFRA(-8%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.62% (StdDev 3.24%) | Hourly BBV | 0 () | Intraday Trend | -6.1% | | | |
|
Resistance Level | $13.69 | 5 Day Moving Average | $13.55(-5.02%) | 10 Day Moving Average | $13.83(-6.94%) | 20 Day Moving Average | $13.69(-5.99%) | To recent high | -10.6% | To recent low | 17.3% | Market Cap | $3.323b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |